

## Supplementary Online Content

Haseeb M, Chhatwal J, Xiao J, Jirapinyo P, Thompson CC. Semaglutide vs endoscopic sleeve gastroplasty for weight loss. *JAMA Netw Open*. 2024;7(4):e246221. doi:10.1001/jamanetworkopen.2024.6221

**eFigure 1.** Simplified State Transition Diagrams for Semaglutide and Endoscopic Sleeve Gastroplasty

**eFigure 2.** Cost-Threshold Analysis of ESG Compared to ICER of Semaglutide Over 1 Year Time Horizon, With Willingness-to-Pay Threshold of \$100,000/QALY


**eFigure 3.** Two-Way Sensitivity Analysis

**eTable.** Variable Parameters With Rationale of Their Chosen Distributions


This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure 1. Simplified State Transition Diagrams for Semaglutide and Endoscopic Sleeve Gastroplasty**

**eFigure 1A.** Simplified State Transition Diagram for Semaglutide. QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; BMI, body mass index.




**eFigure 1B.** Simplified State Transition Diagram for Endoscopic Sleeve Gastroplasty. The repeat procedural rate was applied to the model in year 2 for model simplicity. All patients modeled to undergo repeat procedure were subjected to the same risks and costs as the initial procedure, which was also factored in the same year. QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; BMI, body mass index.



**eFigure 2. Cost-Threshold Analysis of ESG Compared to ICER of Semaglutide Over 1 Year Time Horizon, With Willingness-to-Pay Threshold of \$100,000/QALY**


It shows a cost-threshold of \$11,098 at which ESG will be cost-effective compared to semaglutide at 1 year time horizon.



### eFigure 3. Two-Way Sensitivity Analysis


The impact of the annual cost of semaglutide on two-way sensitivity analyses with the following clinically relevant parameters: A: Weight loss with semaglutide, B: Dropout rate with semaglutide, C: Weight loss after ESG, D: Rate of repeat ESG. The results indicate that a change in strategy preference would only occur if the cost of semaglutide is decreased by at least three-fold.

#### 3A:




**3B:**

Two-Way Sensitivity Analysis (WTP= \$100,000/QALY)




### 3C:

Two-Way Sensitivity Analysis (WTP= \$100,000/QALY)



### 3D:



**eTable. Variable Parameters With Rationale of Their Chosen Distributions**

Parameter Type	Distribution Chosen	Rationale
Cost Parameters	Gamma Distribution	Suitable for skewed data, allowing for the accommodation of the long tail of high-cost events typical in healthcare expenditure.
Transition Probabilities	Beta Distribution	Constrained between 0 and 1, matching the nature of probabilities and rates, ideal for parameters such as treatment effectiveness and adverse event rates.
Utility Values	Beta Distribution	Reflects the bounded nature of utility values which are also constrained between 0 and 1, suitable for quality-adjusted life-year (QALY) estimations.
Normal Distribution parameters (e.g. age, weight)	Normal Distribution	Appropriate for parameters that are symmetrically distributed around a mean, often used for biological or human-related continuous variables.